NCT03144661: An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

NCT03144661
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: FGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have FGF19/FGFR4 alteration; Breast cancer patients are only eligible for Part 2, Cohort C
Exclusions: Untreated or unstable brain or CNS metastases
https://ClinicalTrials.gov/show/NCT03144661

Comments are closed.

Up ↑